Table 3 Application of stem cell exosomes in cancer treatment
From: Tumorigenic and tumoricidal properties of exosomes in cancers; a forward look
Source of SCs-Exo | Intervention/Condition | Type of Cancer | Type of Study/ Animal or cell line | Outcome | Ref |
|---|---|---|---|---|---|
BM‑MSCs-Exos | miR-193a delivery | Lung cancer | In vivo/ Nude BALB/c mice | Suppression of the invasion, migration, and proliferation, reducing cisplatin resistance via downregulating LRRC1 | [225] |
MSCs-Exos | Injection of menstrual MSCs-Exo into the base of the tumor in a dose-dependent manner | Oral squamous cell carcinoma | In vivo/ Syrian golden hamsters | Inhibition of tumor growth and angiogenesis via VEGF suppression | [237] |
MSCs-Exos | miR-143 delivery | Osteosarcoma | In vitro/ Human osteosarcoma cell line 143B | Reduction of the migration | [238] |
BM‑MSCs-Exos | Paclitaxel delivery | Breast cancer | In vivo/ Nude BALB/c mice | Inhibition of tumorigenesis | [239] |
MSCs-Exos | Intravenous injection of doxorubicin-loaded in MSCs-Exo (DOX@exosome-apt) | Colon cancer | In vivo/ BALB/c mice | Inhibition of tumor growth | [226] |
AD-MSCs-Exos | Intravenous injection of miR-199a-loaded in AD-MSCs-Exo | Hepatocellular carcinoma | In vivo/ Nude BALB/c mice | Inhibition of mTOR pathway and improvement of HCC chemosensitivity | [240] |
UC-MSCs-Exos | miR-302a-overexpressing in hUCMSC | Endometrial cancer | In vitro/ Human endometrial cancer cell lines ISK and ECC-1 | Inhibition of the cyclin D1 expression, suppression of AKT signaling pathway, Inhibition of cell proliferation and migration | [241] |
BM‑MSCs-Exos | miR-222-3p delivery | Acute myeloid leukemia (AML) | In vitro/ AML cell line THP-1 | Suppression of cell proliferation and promotion of apoptosis by targeting IRF2/INPP4B | [242] |
MSCs-Exos | miR-23b-5p delivery | Acute myeloid leukemia (AML) | In vitro/ AML cell line HL-60, THP-1 | Reduction of the proliferation and induction of apoptosis via inhibition of TRIM14 and PI3K/AKT pathway | [243] |
BM‑MSCs-Exos | Exosome-based dual delivery biosystem for Galectin-9 siRNA and Oxaliplatin | pancreatic ductal adenocarcinoma (PDAC) | In vivo/ Orthotopic PDAC mice | Induction of ICD, reversing the suppressive tumor immune microenvironment, enhancing immunotherapy effectiveness via inhibiting M2 macrophage polarization and the recruitment of cytotoxic T lymphocytes | [244] |
UC-MSCs-Exos | miRNA-182 delivery | clear cell renal cell carcinoma (ccRCC) | In vivo/ Orthotopic ccRCC mouse model | Increasing cancer cell death by increasing the NK and T cell proliferation, inhibition of metastasis, and growth of tumors | [245] |
MSCs-Exos | TRAIL and Cabazitaxel (CTX) delivery | Oral squamous cell carcinoma | In vivo/ Mouse | Inducing apoptosis by inhibiting the PI3K/Akt/mTOR signaling pathway | [246] |
BM‑MSCs-Exos | miR-199a-Cy3 delivery | Glioma | In vivo/ Nude BALB/c mice | Suppressing glioma development and higher sensitivity to temozolomide by inhibiting AGAP2 expression | [229] |
AD-MSCs-Exos | pre-transfecting miR-1236 inhibitor into the AD-MSCs and Exo isolation (AD-MSCs-Exo /miR-1236 inhibitor) | Breast cancer | In vitro/ DDP-resistant BC cell lines MCF-7 and MDA-MB-231 | Impairing cisplatin (DDP) resistance Through Conveying miR-1236 and suppressing SLC9A1 and the Wnt/β-Catenin Signaling | [247] |
BM‑MSCs-Exos | Exosomal circ_0030167 | Pancreatic cancer |  | Reduction of the invasion, migration, and proliferation of PC cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis | [248] |
UC-MSCs-Exos | miR-451a and ADAM10 delivery | Hepatocellular carcinoma | In vitro/ Hep3B and SMMC-7721 cell lines | limitation of the EMT of hepatocellular carcinoma (HCC) cells by targeting ADAM10 | [249] |
BM-MSC-Exos | miR-9-3p delivery | Bladder cancer | In vivo/ BALB/c nude mice | Inhibition of the expression of EMS1, inhibiting the progression of bladder cancer | [250] |
UC-MSCs-Exos | miR-424 delivery | Ovarian cancer | In vivo/ | Inhibition of the proliferation, migration, invasion, and angiogenesis of ovarian tumors | [19] |